Diabetic Macular Edema Pipeline Analysis Demonstrates Novel 60+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight's, "Diabetic Macular Edema Pipeline Insight, 2023," report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in the Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including Diabetic Macular Edema clinical trials and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Diabetic Macular Edema Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Diabetic Macular Edema clinical trials studies, Diabetic Macular Edema NDA approvals (if any), and product development activities comprising the technology, Diabetic macular edema collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Diabetic Macular Edema Pipeline Report

• DelveInsight's Diabetic Macular Edema pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for Diabetic Macular Edema treatment.

• The leading Diabetic Macular Edema Companies includes Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, AsclepiX Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others

• Promising Diabetic Macular Edema Pipeline Therapies includes MYL-1701P, Eylea, REGN910-3, Sirolimus, MS-R001 (rapamycin), EXN407, Laser Photocoagulation, Teprotumumab, Brolucizumab, Aflibercept, and others.

• The Diabetic Macular Edema companies and academics are working to assess challenges and seek opportunities that could influence Diabetic macular edema R&D. The Diabetic Macular Edema pipeline therapies under development are focused on novel approaches to treat/improve Diabetic macular edema.


To explore more information on the latest breakthroughs in the Diabetic Macular Edema Pipeline treatment landscape of the report, click here @ Diabetic Macular Edema Pipeline Outlook- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Macular Edema Overview

Diabetic Macular Edema (DME) is an eye condition which can occur in people living with diabetes - both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, fluid can leak into the center of the macula, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. Vision changes due to DME are: Blurred vision, Double vision, and Sudden increase in eye floaters.

Recent Developmental Activities in the Diabetic Macular Edema Treatment Landscape

• Recent randomized clinical trials have shown anti-vascular endothelial growth factor (VEGF) therapy improved visual acuity and macular swelling, and currently, it has become the first line of the treatment of DME. Anti-VEGF drugs have become the gold standard for the treatment of DME.

• Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, implants, or injections of sustained-release corticosteroids into or around the eye.

• OPT-302 (Opthea Limited) binds to VEGF receptor 2 and 3, neutralizing the activity of VEGF-C and -D and is being developed by the company for the treatment of patients with Diabetic Macular Edema.

• ALG-1001 (Allegro Ophthalmics) is a first-in-class integrin peptide therapy. The molecule is able to bind specific integrin receptor sites and works by affecting multiple angiogenic pathways and inflammation. ALG-1001 showed promising results in the phase IIb clinical trial that evaluated it as a sequential therapy or in combination with bevacizumab in patients with DME.


For further information, refer to the detailed Diabetic Macular Edema Unmet Needs, Diabetic Macular Edema Market Drivers, and Diabetic Macular Edema Market Barriers, click here for Diabetic Macular Edema Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic macular edema Emerging Drugs Profile

• MYL-1701P: Mylan Pharmaceuticals
MYL-1701P (also referred to as M710, as part of a partnership with Momenta Pharmaceuticals) is perhaps the aflibercept biosimilar that is furthest along in the development process. It is currently the subject of a 324-patient phase III trial. Mylan is to handle development and commercialization.

• KSI-301: Kodiak sciences
KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform KSI-301 is designed to have extended ocular half-life, higher potency, and improved ocular tissue bioavailability. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their DME with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to halt and reverse DR progression with long-term efficacy that can reduce the risk of vision-threatening complications from DR. The Phase III GLEAM and GLIMMER studies are global, multi-center, randomized studies designed to evaluate the efficacy, durability and safety of KSI-301 in patients with treatment-naïve diabetic macular edema (DME).

• CT-P42: Celltrion
CT-P42, an aflibercept biosimilar referencing Regeneron's Eylea. The trial will enroll 300 patients with diabetic macular edema, and aims to compare CT-P42's efficacy, safety, pharmacokinetics, and immunogenicity against Eylea.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of diabetic macular edema (DME)

Diabetic Macular Edema Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Diabetic macular edema. The companies which have their Diabetic macular edema drug candidates in the most advanced stage, i.e. Phase III include, Mylan Pharmaceuticals.

Request a sample and discover the recent advances in Diabetic Macular Edema Ongoing Clinical Trial Analysis and Medications, click here @ Diabetic Macular Edema Treatment Landscape- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diabetic Macular Edema Pipeline Report

• Coverage- Global

• Diabetic Macular Edema Companies- Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, AsclepiX Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.

• Diabetic Macular Edema Pipeline Therapies- MYL-1701P, Eylea, REGN910-3, Sirolimus, MS-R001 (rapamycin), EXN407, Laser Photocoagulation, Teprotumumab, Brolucizumab, Aflibercept, and others.


• Diabetic Macular Edema Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Diabetic Macular Edema Market Drivers and Diabetic Macular Edema Market Barriers, click here @ Diabetic Macular Edema Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic macular edema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. MYL-1701P: Mylan Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Diabetic macular edema Key Companies
17. Diabetic macular edema Key Products
18. Diabetic macular edema- Unmet Needs
19. Diabetic macular edema- Market Drivers and Barriers
20. Diabetic macular edema- Future Perspectives and Conclusion
21. Diabetic macular edema Analyst Views
22. Diabetic macular edema Key Companies
23. Appendix

Got Queries? Find out the related information on Diabetic Macular Edema Mergers and acquisitions, Diabetic Macular Edema Licensing Activities @ Diabetic Macular Edema Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.